Drug treatment for spinal muscular atrophy type I-Reference-Cited by-同舟云学术

Drug treatment for spinal muscular atrophy type I

Published:2012-04-18 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wadman Renske I¹,Bosboom Wendy MJ²,van der Pol W Ludo¹,van den Berg Leonard H¹,Wokke John HJ¹,Iannaccone Susan T³,Vrancken Alexander FJE¹

Affiliation:

1. University Medical Center Utrecht; Department of Neurology; Rudolf Magnus Institute for Neuroscience Universiteitsweg 100 Utrecht Netherlands 3584 CG

2. Sint Lucas Andreas Hospital; Department of Neurology; Jan Tooropstraat 164 Amsterdam Netherlands 1061 AE

3. University of Texas Southwestern Medical Center; Department of Pediatrics; 5323 Harry Hines Boulevard Dallas Texas USA 75390

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD006281.pub4/fullpdf

Reference97 articles.

1. A phase 1 trial of riluzole in spinal muscular atrophy;Russman;Archives of Neurology,2003

2. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate;Brichta;Annals of Neurology,2006

3. Chang JG Tsai FJ Wang WY Jong YJ Treatment of spinal muscular atrophy by hydroxyurea American Journal of Human Genetics 2002 2402

4. Franz DN Tudor CA Samaha FJ A phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy Annals of Neurology 1995 546

5. Phase II open label study of valproic acid in spinal muscular atrophy;Swoboda;PLoS One,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen;Biology Direct;2023-09-13

2. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data;European Journal of Paediatric Neurology;2022-07

3. Novel therapies for spinal muscular atrophy are likely changing the patient phenotype;The Spine Journal;2020-12

4. Cell-Based Therapy for Spinal Muscular Atrophy;Advances in Experimental Medicine and Biology;2020

5. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2–4 (SPACE trial);BMJ Open;2018-07